Holen Sie sich die Stockscreener-App
0.9104
42.63%
0.2721
Schlusskurs vom Vortag:
$0.6383
Offen:
$0.797
24-Stunden-Volumen:
30.65M
Relative Volume:
19.83
Marktkapitalisierung:
$6.39M
Einnahmen:
$5.75M
Nettoeinkommen (Verlust:
$-38.96M
KGV:
-0.073
EPS:
-12.47
Netto-Cashflow:
$-32.63M
1W Leistung:
+43.82%
1M Leistung:
+14.39%
6M Leistung:
-77.47%
1J Leistung:
-85.97%
1-Tages-Spanne:
$0.7013
$1.14
1-Wochen-Bereich:
$0.6076
$1.14
52-Wochen-Spanne:
$0.6076
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Vergleichen Sie KALA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.9104 | 5.24M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.17 | 109.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.61 | 82.75B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.12 | 56.78B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.63 | 56.52B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.51 | 44.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-30 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | Eingeleitet | Mizuho | Outperform |
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
[Form 3] KALA BIO, Inc. Initial Statement of Beneficial Ownership - Stock Titan
[Form 4] KALA BIO, Inc. Insider Trading Activity - Stock Titan
Critical Review: REGENXBIO (NASDAQ:RGNX) versus KALA BIO (NASDAQ:KALA) - Defense World
What Sparked KALA BIO's Nearly 38% Surge Overnight? - Benzinga
Kala Bio IncOn Nov 21, board terminated without cause the employment of Mary Reumuth, company's chief financial officer - MarketScreener
KALA BIO, Inc. Announces Executive and Board Changes - TradingView
[8-K] KALA BIO, Inc. Reports Material Event | KALA SEC FilingForm 8-K - Stock Titan
Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits
KALA BIO, Inc. announced that it expects to receive $6 million in funding - MarketScreener
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What drives KALA BIO Inc stock priceMarket Rumors and News & Minimal Investment Portfolio Growth - earlytimes.in
Real time scanner hits for KALA BIO Inc. explainedEarnings Growth Summary & Weekly High Conviction Ideas - newser.com
KALA BIO: Q3 Earnings Snapshot - Connecticut Post
Is KALA BIO Inc. stock vulnerable to regulatory risksWeekly Trend Summary & Consistent Growth Equity Picks - newser.com
Chart based exit strategy for KALA BIO Inc.Trade Risk Assessment & Proven Capital Preservation Methods - newser.com
Will KALA BIO Inc. stock outperform international peersWeekly Investment Report & Weekly High Conviction Ideas - newser.com
Risk vs reward if holding onto KALA BIO Inc.Portfolio Update Summary & Free Risk Controlled Daily Trade Plans - newser.com
Is KALA BIO Inc. stock trading at a premium valuation2025 Volume Leaders & Free Real-Time Volume Trigger Notifications - newser.com
KALA BIO, Inc. SEC 10-Q Report - TradingView
[10-Q] KALA BIO, Inc. Quarterly Earnings Report | KALA SEC FilingForm 10-Q - Stock Titan
Applying Elliott Wave Theory to KALA BIO Inc.Trade Exit Summary & Weekly High Return Forecasts - newser.com
Best data tools to analyze KALA BIO Inc. stockPortfolio Performance Report & Accurate Buy Signal Alerts - newser.com
Is KALA BIO Inc. stock supported by innovation pipelineWeekly Trend Report & Fast Gain Stock Tips - newser.com
Is KALA BIO Inc. stock a contrarian buyGap Down & Free High Accuracy Swing Entry Alerts - newser.com
Real time alert setup for KALA BIO Inc. performanceJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
What to do if you’re stuck in KALA BIO Inc.Trade Signal Summary & Free Community Supported Trade Ideas - newser.com
Will KALA BIO Inc. stock outperform value stocksJuly 2025 Recap & AI Enhanced Trading Alerts - newser.com
Kala Pharmaceuticals Delays Quarterly Report Filing - MSN
Detecting support and resistance levels for KALA BIO Inc.2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
[NT 10-Q] KALA BIO, Inc. SEC Filing - Stock Titan
Return on assets % of KALA BIO, Inc. – HAM:27F0 - TradingView
Long term debt to total assets ratio of KALA BIO, Inc. – HAM:27F0 - TradingView
Is KALA BIO Inc. stock a good choice for value investorsOptions Play & Long-Term Safe Investment Ideas - Fundação Cultural do Pará
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kala Bio Inc-Aktie (KALA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
0.76%
2.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):